Skip to content

Management of Amavata with Simhanada guggulu .

To study the NIDAN-SAMPRAPTI of Amavata w.s.r to Rheumatoid Arthritis and evaluate the effect of Simhanada guggulu

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027203
Enrollment
20
Registered
2020-08-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: Simhanada Guggulu: 1.5 gm dose is given twice a day with Eranda oil as anupana for 45 days. Reference: Chakradutta Control Intervention1: Not Applicable: Not Applicable

Sponsors

Principal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i.Patients willing to participate in trial. ii.Patient in the age group between 20â?? 60 years, irrespective of sex and socioeconomic status. iii.Patients having signs and symptoms of â??Amavata rogaâ?? (Rheumatoid Arthritis).

Exclusion criteria

Exclusion criteria: i.Patients not willing for the trial. ii.Patients suffering from paralysis. iii.Patient with extremely reduced joint space. iv.Patient having severe crippling deformity. v.Patient with bone deformity. vi.Patients having any type of arthopathy such as Neoplasm of supine, Gout, Ankylosing spondylosis, Traumatic arthritis and Pyogenic osteomylitis etc. vii.Patients having associated cardiac disease, Tuberculosis, Diabetes mellitus, Malignant Hypertension, Renal function Impairment, Hypothyroidism, RHD etc. viii.Pregnant lactating mother.

Design outcomes

Primary

MeasureTime frame
Fulfillment of objective and subjective criteriaTimepoint: 45 Days

Secondary

MeasureTime frame
General feeling of well beingTimepoint: 45 Days

Countries

India

Contacts

Public ContactDr Archana Kumari

Rajiv Gandhi Government Post Graduate Ayurvedic College and Hospital,Paprola

drdalipsharma@gmail.com9418047146

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026